Literature DB >> 17719859

Medical options for treating perianal Crohn's disease.

L Griggs1, D A Schwartz.   

Abstract

Perianal Crohn's disease can cause significant morbidity for patients affected by the disease. However, diagnostic modalities and treatment options have progressed changing the goals of treatment from fistula "improvement" to complete cessation of drainage. Fistula closure and fibrosis of the fistula track is achieved in some patients. Furthermore, treatment has become a combined effort between medical physicians and surgeons. Simple disease can be treated with medical therapy alone consisting of antibiotics and immunomodulators. Infliximab should be added to refractory simple disease or simple disease with the presence of inflammation. If complex fistula disease is evident a surgical evaluation should also be done to determine if intervention is indicated. Complex disease should be treated with antibiotics, immunomodulators and biologic therapy from the onset. This review will summarise current data regarding medical options for treatment of fistulising Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17719859     DOI: 10.1016/j.dld.2007.07.156

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  5 in total

1.  A multidisciplinary team model of caring for patients with perianal Crohn's disease incorporating a literature review, topical therapy and personal practice.

Authors:  Vikki Garrick; Emily Stenhouse; Graham Haddock; Richard K Russell
Journal:  Frontline Gastroenterol       Date:  2012-12-14

2.  Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: a single-centre experience.

Authors:  L Guidi; C Ratto; S Semeraro; I Roberto; I De Vitis; A Papa; M Marzo; A Parello; G Foglietto; G B Doglietto; G B Gasbarrini; G Fedeli
Journal:  Tech Coloproctol       Date:  2008-06-10       Impact factor: 3.781

3.  Managing perianal Crohn's fistula in the anti-TNFα era.

Authors:  P Tozer; D W Borowski; A Gupta; N Yassin; R Phillips; A Hart
Journal:  Tech Coloproctol       Date:  2015-08-12       Impact factor: 3.781

Review 4.  The impact of thiopurines on surgical outcomes in inflammatory bowel disease: do they make a difference?

Authors:  Vivek Chhaya; Richard Pollok
Journal:  F1000Prime Rep       Date:  2013-11-01

Review 5.  Review of local injection of anti-TNF for perianal fistulising Crohn's disease.

Authors:  Samuel O Adegbola; Kapil Sahnan; Philip J Tozer; Robin Ks Phillips; Omar D Faiz; Janindra Warusavitarne; Ailsa Hart
Journal:  Int J Colorectal Dis       Date:  2017-09-12       Impact factor: 2.571

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.